Associated Genetic Biomarkers
Neuroendocrine tumors most frequently harbor alterations in MEN1, TP53, ARID1A, KMT2D, and ATM .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, MEN1 Mutation, and KMT2D Mutation are the most common alterations in neuroendocrine tumor .
There are 32 clinical trials for neuroendocrine tumor, of which 25 are open and 7 are completed or closed. Of the trials that contain neuroendocrine tumor as an inclusion criterion, 2 are early phase 1 (1 open), 5 are phase 1 (3 open), 4 are phase 1/phase 2 (2 open), 17 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), 1 is phase 3 (1 open), and 2 are no phase specified (2 open).
SSTR2, SSTR1, and SSTR3 are the most frequent gene inclusion criteria for neuroendocrine tumor clinical trials .
Cabozantinib, lutetium lu 177 dotatate, and pembrolizumab are the most common interventions in neuroendocrine tumor clinical trials.
Significant Genes in Neuroendocrine Tumor
BRCA1 is altered in 1.22% of neuroendocrine tumor patients .
BRCA1 is an inclusion eligibility criterion in 1 clinical trial for neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) .
BRCA2 is altered in 2.79% of neuroendocrine tumor patients .
BRCA2 is an inclusion eligibility criterion in 1 clinical trial for neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.